Commonwealth of Pennsylvania Public School Empls Retrmt SYS Reduces Stake in Johnson & Johnson (JNJ)
Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,954 shares of the company’s stock after selling 301 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Johnson & Johnson were worth $17,967,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new stake in Johnson & Johnson during the third quarter worth $104,000. Hefty Wealth Partners raised its stake in Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock worth $132,000 after buying an additional 951 shares in the last quarter. Wechter Feldman Wealth Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter worth $209,000. New Capital Management LP bought a new stake in Johnson & Johnson during the fourth quarter worth $214,000. Finally, Turner Investments LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $218,000. 65.30% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) opened at 128.07 on Tuesday. Johnson & Johnson has a one year low of $106.36 and a one year high of $129.00. The firm has a 50-day moving average of $119.96 and a 200-day moving average of $117.07. The stock has a market capitalization of $347.50 billion, a PE ratio of 21.59 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.02. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm earned $18.10 billion during the quarter, compared to analysts’ expectations of $18.28 billion. During the same quarter in the previous year, the business earned $1.44 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post $7.04 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th were paid a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend was Friday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 54.42%.
Your IP Address:
A number of research firms have recently weighed in on JNJ. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $124.53 price objective for the company. in a research note on Thursday, February 23rd. Goldman Sachs Group Inc decreased their price objective on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, January 25th. Wells Fargo & Co downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $112.28 to $112.80 in a research note on Thursday, January 26th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $107.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 20th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $124.09.
In other news, VP Paulus Stoffels sold 22,000 shares of the business’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total value of $2,580,380.00. Following the completion of the transaction, the vice president now owns 127,650 shares in the company, valued at $14,972,068.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.11% of the stock is owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.